DK1146874T3 - Vitronectinreceptoragonist - Google Patents

Vitronectinreceptoragonist

Info

Publication number
DK1146874T3
DK1146874T3 DK99960647T DK99960647T DK1146874T3 DK 1146874 T3 DK1146874 T3 DK 1146874T3 DK 99960647 T DK99960647 T DK 99960647T DK 99960647 T DK99960647 T DK 99960647T DK 1146874 T3 DK1146874 T3 DK 1146874T3
Authority
DK
Denmark
Prior art keywords
receptor agonist
vitronectin receptor
vitronectin
agonist
receptor
Prior art date
Application number
DK99960647T
Other languages
Danish (da)
English (en)
Inventor
William H Miller
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1146874T3 publication Critical patent/DK1146874T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
DK99960647T 1998-12-04 1999-12-03 Vitronectinreceptoragonist DK1146874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04
EP99960647A EP1146874B1 (de) 1998-12-04 1999-12-03 Vitronectin rezeptor antagonist

Publications (1)

Publication Number Publication Date
DK1146874T3 true DK1146874T3 (da) 2005-01-31

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99960647T DK1146874T3 (da) 1998-12-04 1999-12-03 Vitronectinreceptoragonist

Country Status (39)

Country Link
US (1) US6495560B1 (de)
EP (1) EP1146874B1 (de)
JP (1) JP4481504B2 (de)
KR (1) KR100620485B1 (de)
CN (1) CN1147300C (de)
AP (1) AP1534A (de)
AR (1) AR035006A1 (de)
AT (1) ATE277043T1 (de)
AU (1) AU754408B2 (de)
BG (1) BG65118B1 (de)
BR (1) BR9915879A (de)
CA (1) CA2353415A1 (de)
CO (1) CO5150166A1 (de)
CZ (1) CZ20011963A3 (de)
DE (1) DE69920518T2 (de)
DK (1) DK1146874T3 (de)
DZ (1) DZ2954A1 (de)
EA (1) EA003254B1 (de)
EG (1) EG24025A (de)
ES (1) ES2229798T3 (de)
HK (1) HK1042037B (de)
HU (1) HUP0104804A3 (de)
ID (1) ID28811A (de)
IL (2) IL143390A0 (de)
MA (1) MA25265A1 (de)
NO (1) NO318895B1 (de)
NZ (1) NZ511876A (de)
OA (1) OA11724A (de)
PE (1) PE20001563A1 (de)
PL (1) PL195973B1 (de)
PT (1) PT1146874E (de)
SI (1) SI1146874T1 (de)
SK (1) SK7452001A3 (de)
TR (1) TR200101654T2 (de)
TW (1) TW482673B (de)
UA (1) UA71586C2 (de)
UY (1) UY25824A1 (de)
WO (1) WO2000033838A1 (de)
ZA (1) ZA200104398B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269821A1 (en) * 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
DE60118025T2 (de) * 2000-10-24 2006-11-23 Merck & Co., Inc. Dibenzoxazepin-alpha-v-integrin-rezeptorantagonist
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058760A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
JP2008524334A (ja) * 2004-12-21 2008-07-10 スミスクライン・ビーチャム・コーポレイション 方法および処方
KR101491938B1 (ko) 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
HRP20211836T1 (hr) 2013-09-24 2022-03-04 Fujifilm Corporation Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
DE69627899T2 (de) * 1995-06-29 2004-05-19 Smithkline Beecham Corp. Integrin-rezeptor-antagonisten
WO1998013278A1 (de) * 1996-09-27 1998-04-02 Merkler, H. Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten
JP2001501951A (ja) * 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
TR200101654T2 (tr) 2002-03-21
AP1534A (en) 2006-01-09
KR100620485B1 (ko) 2006-09-13
UY25824A1 (es) 2001-07-31
EG24025A (en) 2008-03-26
PL195973B1 (pl) 2007-11-30
HUP0104804A3 (en) 2002-12-28
AR035006A1 (es) 2004-04-14
CO5150166A1 (es) 2002-04-29
HUP0104804A2 (hu) 2002-05-29
ZA200104398B (en) 2002-05-29
WO2000033838A1 (en) 2000-06-15
PT1146874E (pt) 2005-02-28
HK1042037A1 (en) 2002-08-02
JP2003523931A (ja) 2003-08-12
PL348702A1 (en) 2002-06-03
JP4481504B2 (ja) 2010-06-16
NZ511876A (en) 2004-02-27
ES2229798T3 (es) 2005-04-16
NO20012732L (no) 2001-08-01
EP1146874B1 (de) 2004-09-22
ID28811A (id) 2001-07-05
SI1146874T1 (en) 2005-04-30
DZ2954A1 (fr) 2004-06-20
EP1146874A1 (de) 2001-10-24
ATE277043T1 (de) 2004-10-15
NO20012732D0 (no) 2001-06-01
US6495560B1 (en) 2002-12-17
CN1147300C (zh) 2004-04-28
CN1334730A (zh) 2002-02-06
BG105651A (en) 2002-02-28
EA200100618A1 (ru) 2001-12-24
EA003254B1 (ru) 2003-02-27
AU754408B2 (en) 2002-11-14
DE69920518D1 (de) 2004-10-28
HK1042037B (zh) 2005-07-29
MA25265A1 (fr) 2001-10-01
SK7452001A3 (en) 2001-12-03
IL143390A0 (en) 2002-04-21
UA71586C2 (en) 2004-12-15
PE20001563A1 (es) 2001-02-09
CA2353415A1 (en) 2000-06-15
DE69920518T2 (de) 2005-09-22
TW482673B (en) 2002-04-11
EP1146874A4 (de) 2002-06-05
KR20010080669A (ko) 2001-08-22
CZ20011963A3 (cs) 2001-11-14
BR9915879A (pt) 2002-02-13
IL143390A (en) 2006-07-05
OA11724A (en) 2005-01-26
BG65118B1 (bg) 2007-03-30
NO318895B1 (no) 2005-05-18
AU1750200A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
IS5706A (is) Adenosín A3 viðtakastillar
DK1019075T3 (da) Beta2-Adrenerge receptoragonister
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
ATE312089T1 (de) Vitronektin rezeptor antagonisten
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
NO20004503D0 (no) Vitronectin-reseptor-antagonister
ATE272632T1 (de) Muskarin-rezeptor antagonisten
NO20001514D0 (no) Vitronectin-reseptor-antagonist
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001515D0 (no) Vitronektin reseptor-antagonist
NO20013997D0 (no) Reseptoranalyse
NO20001407D0 (no) Vitronectin-reseptor-antagonister
DK1146874T3 (da) Vitronectinreceptoragonist
ID26086A (id) Ligan-ligan reseptor 5ht1 azabisiklik
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
NO20010353D0 (no) IL-8 reseptor-antagonist
DK1218005T3 (da) Vitronectinreptorantagonister
DE69830671D1 (de) Integrin-rezeptor-antagonisten
GB9810892D0 (en) Vitronectin receptor antagonists